With Eylea in de­cline, Re­gen­eron awaits FDA ap­proval for high­er dose of block­buster

Re­gen­eron is bank­ing on get­ting a high­er dose of afliber­cept, the Bay­er-part­nered wet AMD drug al­so known as Eylea, to the US mar­ket as soon as next month to stave off low­er sales of a low­er dose.

Eylea sales in the US, where on­ly the 2 mg dose is ap­proved, were down 6% last quar­ter com­pared to Q1 last year, and down 4% com­pared to the pre­vi­ous quar­ter. The com­pa­ny blamed the fall on a va­ri­ety of fac­tors, in­clud­ing high­er sales-re­lat­ed de­duc­tions and in­creased “com­pet­i­tive pres­sure” from the likes of Roche’s Vabysmo (faricimab-svoa).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER